References:
1. Product Information: MILK OF MAGNESIA oral liquid, magnesium hydroxide oral liquid. Humco, Texarkana, TX, 2007.
2. Lima M, Cruz T, Carreiro Pousada J et al: The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes. Diabetes Care 1998; 21:682-686.
3. Peikert A, Wilimzig C & Kohne-Volland R: Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalagia 1996; 16:257-263.
4. Taubert K: Magnesium in migraine. Results of a multicenter pilot study (German). Fortschr Med 1994; 112(24):328-330.
5. Johansson G, Backman U, Danielson BG et al: Biochemical and clinical effects of the prophylactic treatment of renal calcium stones with magnesium hydroxide. J Urol 1980; 124:770-774.
6. Rude RK & Olerich M: Magnesium deficiency: possible role in osteoporosis associated with gluten-sensitive enteropathy. Osteoporosis Int 1996; 6:453-461.
7. Walker AF, De Souza MC, Vickers MF et al: Magnesium supplementation alleviates premenstrual symptoms of fluid retention. J Womens Health 1998; 7(9):1157-1165.
8. AHFS: American Society of Hospital Pharmacists Drug Information. Bethesda, MD; 1994.
9. Benitz WE & Tatro DS: The Pediatric Drug Handbook, 2nd ed. Year Book Medical Publishers, Chicago, IL; 1988.
10. L'Hommedieu CS, Nicholas D, Armes DA et al: Potentiation of magnesium sulfate induced neuromuscular weakness by gentamicin, tobramycin, and amikacin. J Pediatr 1983; 102:629-631.
11. Watson A, Coffey L, Keogh B et al: Severe hypomagnesaemia and hypocalcaemia following gentamicin therapy. Ir Med J 1983; 76:381-383.
12. Pittman J: Magnesium sulphate for pre-eclampsia and a sudden bradycardia. Br J Anaesth 2000; 85:327-328.
13. Product Information: Orlaam(R), levomethadyl. Roxane Laboratories, Inc., Columbus, Ohio, (PI revised 5/2001) reviewed 2/2002.
14. Nix DE, Watson WA, Lener ME et al: Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther 1989a; 46:700-705.
15. Product Information: Nimbex(R) injection, cisatracurium besylate. Glaxo Wellcome Inc, Research Triangle Park, NC; 1998.
16. Snyder SW & Capewell MS: Neuromuscular blockade with magnesium sulfate and nifedipine. Am J Obstet Gynecol 1989; 161: 35-36.
17. Product Information: CellCept(R), mycophenolate mofetil. Roche Laboratories Inc., Nutley, NJ, 1998.
18. Product Information: Cipro(R) XR, extended-release ciprofloxacin tablets. Bayer Corporation, West Haven, CT, 08/2003.
19. Product Information: Spectracef(TM), cefditoren pivoxil. TAP Pharmaceuticals, Inc., Lake Forest, Illinois, 08/2001.
20. Hughes GS, Heald DL, Barker KB et al: The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clin Pharmacol Ther 1989; 46:674-685.
21. Saathoff N, Lode H, Neider K et al: Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother 1992; 36:796-800.
22. Product Information: Nimbex(R) injection, cisatracurium besylate. Glaxo Wellcome Inc, Research Triangle Park, NC; 1998.
23. Aldrete JA, Zahler A & Aikawa JK: Prevention of succinylcholine-induced hyperkalemia by magnesium sulfate. Can Anaesth Soc J 1970; 17:477-484.
24. Ghoneim MM & Long JP: The interaction between magnesium and other neuromuscular blocking agents. Anesthesiology 1970; 32:23.
25. Morris R & Giesecke AH: Potentiation of muscle relaxants by magnesium sulfate therapy in toxemia of pregnancy. South Med J 1968; 61:25.
26. Sinatra RS, Philip BK, Naulty JS et al: Prolonged neuromuscular blockade with vecuronium in a patient treated with magnesium sulfate. Anesth Analg 1985; 64:1220-1222.
27. Saathoff N, Lode H, Neider K et al: Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother 1992; 36:796-800.
28. Patterson TF, Peters J, Levine SM et al: Systemic availability of itraconazole in lung transplantation. Antimicrob Agents Chemother 1996; 40:2217-2220.
29. Product Information: Sporanox(R), itraconazole. Janssen Pharmaceutica Products, L.P., Titusville, New Jersey, 02/2002.
30. Brass C, Galgiani JN, Blaschke TF et al: Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother 1982; 21:151-158.
31. Carlson JA, Mann HJ & Canafax DM: Effect of pH on disintegration and dissolution of ketoconazole tablets. Am J Hosp Pharm 1983; 40:1334-1336.
32. Van der Meer JWM, Keuning JJ, Scheijgrond HW et al: The influence of gastric acidity on the bioavailability of ketoconazole. J Antimicrob Chemother 1980; 6:552-554.
33. Product Information: Agenerase(R), amprenavir. Glaxo Wellcome Inc., Research Triangle Park, NC, 2000.
34. Product Information: Lexiva(TM), fosamprenavir. GlaxoSmithKline, Research Triangle Park, NC, 10/2003.
35. Baldwin JR, Borin MT, Wang Y et al: Effects of food and antacid on bioavailability of the protease inhibitor PNU-140690 in healthy volunteers (abstract). 5th Conf Retrovir Oppor Inf, Chicago, February 1-5, 1998.
36. Product Information: Boniva(TM), ibandronate sodium tablets. GlaxoSmithKline, Research Triangle Park, NC, 05/2003.
37. Product Information: Skelid(R), tiludronate. Sanofi Pharmaceuticals, Inc., New York, NY, 1998.
38. Delhotal-Landes B, Cournot A, Vermerie N et al: The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drug Metab Pharmacokinet 1991; Spec No 3:315-320.
39. Product Information: Carafate(R), sucralfate. Hoechst Marion Roussel, Inc., Kansas City, MO, 1996.
40. Product Information: Levsin(R), hyoscyamine sulfate. Schwarz Pharma, Inc., Milwaukee, WI, 1996.
41. Fernandez PC & Kovnat PJ: Metabolic acidosis reversed by the combination of magnesium hydroxide and cation exchange resin. N Engl J Med 1972; 286:23.
42. Madias NE & Levey AS: Metabolic alkalosis due to absorption of "non-absorbable" antacids. Am J Med 1983; 74:155-158.
43. Schroeder ET: Alkalosis resulting from combined administration of a "non-systemic" antacid and a cation-exchange resin. Gastroenterology 1969; 56:868.
44. Ziessman HA: Alkalosis and seizure due to a cation exchange resin and magnesium hydroxide. South Med J 1976; 69:497-499.
45. Shah J, Fratis A, Ellis D et al: Effect of food and antacid on absorption of orally administered ticlopidine hydrochloride. J Clin Pharmacol 1990; 30:733-736.
46. Feldman S & Carlstedt BC: Effects of antacid on absorption of enteric-coated aspirin. JAMA 1974; 227:660.
47. Gaspari F, Vigano G, Tocatelli M et al: Influence of antacid administrations on aspirin absorption in patients with chronic renal failure on maintenance hemodialysis. Am J Kidney Dis 1988; 11:338-342.
48. Gibaldi M, Grundhofer B & Levy G: Effect of antacids on pH of urine. Clin Pharmacol Ther 1974; 16:520-525.
49. Hansten PD & Hayton WL: Effect of antacid and ascorbic acid on serum salicylate concentration. J Clin Pharmacol 1980; 20:326-331.
50. Levy G, Lampman T, Kamath BL et al: Decreased serum salicylate concentrations in children with rheumatic fever treated with antacids. N Engl J Med 1975; 293:323.
51. Shastri RA: Effect of antacids on salicylate kinetics. Int J Clin Pharmacol Ther Toxicol 1985; 23:480-484.
52. Strickland-Hodge B, Thomas TR, Gould WA et al: The effects of antacids on enteric-coated salicylate preparations. Rheumatol Rehabil 1976; 15:148-152.
53. Wagstaff AJ, Benfield P & Monk JP: Colloidal bismuth subcitrate: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs 1988; 36:132-157.
54. Product Information: Hectorol(R), doxercalciferol. Bone Care International, Inc., Madison, WI, 2000.
55. Product Information: SPRYCEL(R) oral tablets, dasatinib oral tablets. Bristol-Myers Squibb, Princeton, NJ, 2008.
56. Product Information: TARCEVA(R) oral tablets, erlotinib oral tablets. OSI Pharmaceuticals Inc, Melville, NY, 2008.
57. Product Information: PROMACTA(R) oral tablets, eltrombopag oral tablets. Glaxo Smith Kline, Research Triangle Park,, NC, 2008.